Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab for moderate-to-severe face and neck atopic dermatitis
2025-525133-31-00Phase 3Authorised
- Sponsor
- Almirall
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Lebrikizumab with Placebo (2 arms). Primary endpoint: IGA response at Week 16. Planned start Oct 2026; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-525133-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525133-31-00.